Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 18, 2026
DataAggregated Company Financials
Companies7
  • 7D-1.7%
  • 3M5.3%
  • 1Y-10.1%
  • YTD-4.3%

Over the last 7 days, the Life Sciences industry has dropped 1.7%, driven by pullbacks in Siegfried Holding and Lonza Group of 13% and 1.1%, respectively. Meanwhile, PolyPeptide Group actually outperformed within the industry, gaining 8.1% in the last week. The industry has fallen 10% in the last year. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 18 Jun 2026CHF 46.8bCHF 10.1bCHF 1.1b35.8x42.8x4.6x
Sat, 16 May 2026CHF 46.0bCHF 10.1bCHF 1.1b37x42.1x4.5x
Mon, 13 Apr 2026CHF 48.3bCHF 10.1bCHF 1.1b33.4x42.2x4.8x
Wed, 11 Mar 2026CHF 46.3bCHF 10.1bCHF 1.3b28.3x35.8x4.6x
Fri, 06 Feb 2026CHF 49.6bCHF 10.1bCHF 1.3b32.4x38.9x4.9x
Sun, 04 Jan 2026CHF 49.3bCHF 10.6bCHF 1.1b29.7x44.9x4.6x
Tue, 02 Dec 2025CHF 49.9bCHF 10.6bCHF 1.1b28.3x45.4x4.7x
Thu, 30 Oct 2025CHF 51.6bCHF 10.6bCHF 1.1b31.4x47x4.8x
Sat, 27 Sep 2025CHF 48.4bCHF 10.6bCHF 1.1b30.8x44x4.5x
Mon, 25 Aug 2025CHF 53.7bCHF 10.7bCHF 1.1b36.5x48.7x5x
Wed, 23 Jul 2025CHF 51.7bCHF 10.1bCHF 1.0b32.2x49.8x5.1x
Fri, 20 Jun 2025CHF 52.3bCHF 10.1bCHF 1.0b33x50.3x5.2x
Sun, 18 May 2025CHF 53.3bCHF 10.1bCHF 1.0b32.9x51.3x5.3x
Tue, 15 Apr 2025CHF 48.8bCHF 10.1bCHF 1.0b28.5x47.5x4.8x
Thu, 13 Mar 2025CHF 51.4bCHF 10.1bCHF 1.0b33.3x50.9x5.1x
Sat, 08 Feb 2025CHF 57.7bCHF 10.1bCHF 1.0b35.9x57.3x5.7x
Mon, 06 Jan 2025CHF 52.7bCHF 10.2bCHF 943.5m36x55.8x5.2x
Wed, 04 Dec 2024CHF 52.9bCHF 10.2bCHF 943.6m40x56.1x5.2x
Fri, 01 Nov 2024CHF 54.5bCHF 10.2bCHF 943.4m41.8x57.8x5.3x
Sun, 29 Sep 2024CHF 55.9bCHF 10.2bCHF 943.4m43.2x59.3x5.5x
Tue, 27 Aug 2024CHF 57.7bCHF 10.2bCHF 936.9m45.1x61.6x5.6x
Thu, 25 Jul 2024CHF 55.5bCHF 10.3bCHF 1.0b48x55.4x5.4x
Sat, 22 Jun 2024CHF 51.3bCHF 10.3bCHF 1.0b44.2x51.1x5x
Mon, 20 May 2024CHF 56.1bCHF 10.3bCHF 1.0b46x56x5.5x
Wed, 17 Apr 2024CHF 55.9bCHF 10.3bCHF 1.0b44.2x55.7x5.4x
Fri, 15 Mar 2024CHF 53.5bCHF 10.2bCHF 1.0b45.3x53.3x5.2x
Sun, 11 Feb 2024CHF 48.1bCHF 10.2bCHF 1.0b42.5x47.2x4.7x
Tue, 09 Jan 2024CHF 40.7bCHF 9.8bCHF 1.5b31.2x27.3x4.2x
Thu, 07 Dec 2023CHF 39.6bCHF 9.8bCHF 1.5b29.3x26.5x4.1x
Sat, 04 Nov 2023CHF 38.8bCHF 9.8bCHF 1.5b27.3x26x4x
Mon, 02 Oct 2023CHF 46.5bCHF 9.8bCHF 1.5b32.2x31.2x4.8x
Wed, 30 Aug 2023CHF 52.4bCHF 9.8bCHF 1.5b36.3x35.1x5.4x
Fri, 28 Jul 2023CHF 52.6bCHF 9.8bCHF 1.5b35.8x34x5.4x
Sun, 25 Jun 2023CHF 55.2bCHF 9.7bCHF 1.6b34.3x33.7x5.7x
Price to Earnings Ratio

33.7x


Total Market Cap: CHF 55.2bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.8x which is lower than its 3-year average PE of 46.4x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market2.53%
Healthcare1.36%
Life Sciences-1.66%
Clinical Research and Equipment-1.66%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
PPGN PolyPeptide GroupCHF 36.558.1%
+CHF 90.8m		72.8%PS3.4x
XLS Xlife SciencesCHF 24.5010.4%
+CHF 13.1m		21.3%PS507.4x
BANB Bachem HoldingCHF 67.100.1%
+CHF 7.5m		16.2%PE33.8x

Latest News

LONN
CHF 493.30
Lonza Group
7D
-1.1%
1Y
-11.8%
SFZN
CHF 67.00
Siegfried Holding
7D
-12.8%
1Y
-28.8%
Narrative Update • Jun 15

SFZN: Raised 2026 Sales Guidance Will Support Future Rerating Potential

Analysts have reduced the fair value estimate for Siegfried Holding from CHF 136.00 to CHF 126.00, citing updated assumptions on discount rates, revenue growth, profit margins and the future P/E multiple that align with recent Street research, including a CHF 4 price target adjustment. What's in the News Siegfried AG raised its earnings guidance for 2026, now expecting high single digit % growth in group net sales in local currencies, compared with its previous outlook for low single digit % growth.
TECN
CHF 149.90
Tecan Group
7D
-2.4%
1Y
-7.8%
Narrative Update • Jun 14

TECN: Reset CHF 205 Goal Will Support Future Earnings Re Rating

Analysts have reduced their price target for Tecan Group from CHF 335.08 to CHF 205.00, citing updated assumptions for revenue growth, profit margins and future P/E multiples, along with recent Street research cuts from CHF 10 and CHF 1. Analyst Commentary Recent Street research has focused on recalibrating Tecan Group’s valuation framework, with price targets adjusted to reflect updated views on revenue growth, margins and P/E multiples.
SKAN
CHF 49.30
SKAN Group
7D
-2.2%
1Y
-31.5%
BANB
CHF 67.10
Bachem Holding
7D
0.1%
1Y
16.2%
Narrative Update • Jun 05

BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework

Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.
PPGN
CHF 36.55
PolyPeptide Group
7D
8.1%
1Y
72.8%
XLS
CHF 24.50
Xlife Sciences
7D
10.4%
1Y
21.3%